Healthcare Industry News: HSMN NewsFeed
News Release - November 10, 2026
GT Medical Technologies Welcomes New GammaTile(R) Center of Excellence Program Designation
Recognizing exceptional leadership in patient education and clinical skill in the GammaTile procedureTEMPE, Ariz., Nov. 10, 2026 -- (Healthcare Sales & Marketing Network) -- GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, today announced AdventHealth Daytona Beach as the latest GammaTile®?Center of Excellence Program designation.
The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.
The following physicians are now recognized with achievement:
- Shiv Chetan Desai, MD, MBA, Radiation Oncologist, ACR Regional Medical Director for Radiation Oncology, NRG Oncology Institutional Principal Investigator for AdventHealth East Florida Division
- Nicolette Huntley, MD, Radiation Oncologist
- John Reilly, MD, Radiation Oncologist
- Federico Vinas, MD, Neurosurgeon, Brain Tumors Director of Neurosurgery
- Wissam Elfallal, DO, FACOS, Cranial and Skull Base Surgery Neurosurgeon, Chair of Spine, American College of Osteopathic Surgeons
- Erinç Aktüre, MD, Cerebrovascular and Skull Base Tumors Neurosurgeon
- Gregory Velat, MD, Neurosurgeon
"This designation reflects the dedication and hard work of our Neurosurgery and Radiation Oncology teams. We have built and achieved this together," said Dr. Shiv Desai, MD, MBA, Radiation Oncologist at AdventHealth Daytona Beach. "GammaTile lets us begin radiation therapy at the moment of surgery, so our patients don't have to wait weeks for their next phase of treatment. Being recognized as a Center of Excellence affirms the expertise and coordination our team brings to every case and every patient."
GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1
About GammaTile
GammaTile is FDA-cleared for newly diagnosed malignant (cancerous) and recurrent brain tumors and has been adopted by more than 150 leading centers across the United States, underscoring its growing acceptance in both academic and community healthcare settings.2 For more information, visit gammatile.com and follow @GammaTile on Facebook, Instagram, LinkedIn and X.
About GT Medical Technologies, Inc.
GT Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard-of-care.
Media Contact
Dawn Fallon
New Dawn Communications LLC
Dfallon@newdawncomms.com
732-771-7808
References
1. Garcia MA et al. J Neurooncol. 166:203-212 (2024).
2. Data on file. GT Medical Technologies, Inc.
Source: GT Medical Technologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!